ERIC Number: EJ1093170
Record Type: Journal
Publication Date: 2016-Apr
Abstractor: As Provided
Reference Count: 28
Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review
Jain, Seema; Andridge, Rebecca; Hellings, Jessica A.
Journal of Autism and Developmental Disorders, v46 n4 p1344-1353 Apr 2016
Loxapine substitution is a promising option for patients with autism spectrum disorder (ASD) who develop antipsychotic-induced metabolic illness. We performed a chart review of 15 adolescents and adults meeting DSM-IV-TR criteria for ASD, all with antipsychotic-associated weight gain, who received low dose loxapine in an attempt to taper or discontinue the weight gain-associated antipsychotic. Mean weight loss was -5.7 kg, mean BMI reduction was -1.9, and mean triglyceride reduction was -33.7 mg/dl. At chart review, 14 of 15 subjects were rated 2 (Much Improved) or 1 (Very Much Improved) on the Clinical Global Impressions-Improvement scale (CGI-I). Low dose loxapine addition in most cases enabled taper of offending antipsychotics, significantly reversed drug-induced metabolic disturbances and improved irritability.
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Adolescents, Adults, Body Weight, Symptoms (Individual Disorders), Physiology, Mental Health
Springer. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: email@example.com; Web site: http://www.springerlink.com
Publication Type: Journal Articles; Reports - Research
Education Level: N/A
Authoring Institution: N/A